

Capital
TECHNOLOGY

COVID-19 (SARS-CoV-2)

Nucleic Acid Test Kit (Fluorescence PCR Method)



High Sensitivity

No nucleic acid dilution is required, and the LOD is at 150 copies/mL.

Easy to Operation

Reagent thawing, configuration, mixing, and sub-packaging are no longer necessary with the new freeze-dried detection reagent. In order to perform nucleic acid detection, the operator can directly add nucleic acid samples.

Convenient for Storage and Transport

Freeze-dried reagents are stable and do not require low-temperature cold chain transit. Transport and storage costs are considerably minimized.

Microsphere Patent

Exclusive Microsphere Patent

Based on RT-PCR technology, the kit combines the buffer solution, enzyme, primer, and probe used in the amplification reaction into freeze-dried microspheres. It begins testing after preloading the microsphere into a 96-well plate using the PCR tube strip and directly adding the extracted samples to the reaction wells. With strong independence and accurate results, the test results of samples do not interfere with each other. At the same time, the kit may perform tests for the SARS-CoV-2 ORF1ab gene and the N gene.

Test Process

Fill the PCR amplification reagent reaction tube containing the freeze-drying microspheres with 20 uL of nucleic acid samples.	»	Seal the tube	»	Oscillate and centrifuge	»	Load and amplify



Applicable Population

The susptected COVID-19 cases, cluster cases and others require SARS-CoV-2 detection

Product Specification

32	32 tests/kit (eight-strip tube)
96	96 tests/kit (96-well plate)

Applicable Device

01 ABI 7500 Real Time PCR System	02 Hongshi SLAN-96S Real Time PCR System

©2021 CapitalBio Technology. All rights reserved. HWSY-2022-008 V1.0

CAPITALBIO TECHNOLOGY
+86-10-69002900
globalsales@capitalbiotech.com | en.capitalbiotech.com/en/index.html
Add: 88 Kechuang 6th Street, Building c, Yizhuang Biomedical Park, Beijing Economic-Technological Development Area, Beijing 101111, China